| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2025―Apr―08 |
Outpatient utilization trend of bronchodilator and anti-inflammatory agents in the pandemic and beyond |
N. Ipek Kirmizi Sonmez, Onur Gultekin, Ahmet Akici, Yelda Basbug, Volkan Aydin |
| 2 |
[GO] |
2025―Jan―08 |
Mpox virus (MPXV): comprehensive analysis of pandemic risks, pathophysiology, treatments, and mRNA vaccine development |
Sajjad Eslamkhah, Elif Sibel Aslan, Cuneyd Yavas, Nermin Akcalı, Lutfiye Karcıoglu Batur, Asmaa Abuaisha, et al. (+3) Erva Esma Yildirim, Mustafa Solak, Kenneth N. White |
| 3 |
[GO] |
2024―Okt―01 |
A critical review on phytochemicals as antiviral medications for SARS-CoV-2 virus infection |
Manoja Das, Namita Panigrahy |
| 4 |
[GO] |
2024―Aug―29 |
Methylene blue for COVID-19 ARDS: insights from a randomized Clinical Trial |
Zahra Sadat Sanei, Fatemeh Shahrahmani, Behrooz Khaleghi Manesh, Daryoush Hamidi-alamdari, Hassan Mehrad-Majd, Behzad Mavaji Darban, et al. (+2) Seyedeh Motahareh Mirdoosti, Mohsen Seddigh-Shamsi |
| 5 |
[GO] |
2024―Jul―20 |
Sotrovimab in the treatment of coronavirus disease-2019 (COVID-19): a systematic review and meta-analysis of randomized clinical trials |
Ana Flávia da Silva Amorim, Joselin Valeska Martinez Sobalvarro, Larissa Helena Torres, Tiago Marques dos Reis |
| 6 |
[GO] |
2024―Mai―14 |
Adverse drug reactions associated with COVID-19 management |
Vivek Chavda, Payal Dodiya, Vasso Apostolopoulos |
| 7 |
[GO] |
2024―Mai―07 |
Thrombocytopenia risks in ARDS COVID-19 patients treated with high-dose linezolid during vvECMO therapy: an observational study |
Pedja Kovacevic, Dragana Milakovic, Tijana Kovacevic, Vedrana Barisic, Sasa Dragic, Biljana Zlojutro, et al. (+3) Branislava Miljkovic, Katarina Vucicevic, Zeeshan Rizwan |
| 8 |
[GO] |
2024―Jan―05 |
Remdesivir: treatment of COVID-19 in special populations |
Emad Molaei, Ali Molaei, A. Wallace Hayes, Gholamreza Karimi |
| 9 |
[GO] |
2023―Aug―28 |
Hydroxychloroquine and COVID-19 story: is the low-dose treatment the missing link? A comprehensive review and meta-analysis |
Idir Ramdani, Belaid Bouazza |
| 10 |
[GO] |
2023―Jul―21 |
Perceptions of medicinal herbal products during the COVID-19 pandemic period among Saudi patients: a cross-sectional study |
Aisha Nawaf Al balawi, Alaa R. El-Alosey, Jayda G. Eldiasty, Ismail Y. H. Abushalfeh, Angod Ahmed Almasaude, Sahar Abd-El Razik Mosallam, Alaa Elmetwalli |
| 11 |
[GO] |
2023―Jun―26 |
Adverse drug reactions to chloroquine/hydroxychloroquine in combination with azithromycin in COVID-19 in-patients: data from intensive pharmacovigilance in Morocco, 2020 |
Latifa Aït Moussa, Amina Tebaa, Loubna Alj, Houda Sefiani, Fatima Zahra Meski, Asmae Khattabi, Rachida Soulaymani Bencheikh |
| 12 |
[GO] |
2023―Mrz―26 |
Outcomes of high-risk adult outpatients treated with early remdesivir therapy during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron era: experiences from the national centre of Hungary |
Zsófia Gáspár, Bálint Gergely Szabó, Anita Ábrahám, Zsuzsanna Várnai, Noémi Kiss-Dala, János Szlávik, et al. (+3) János Sinkó, István Vályi-Nagy, Botond Lakatos |
| 13 |
[GO] |
2023―Feb―11 |
Long COVID could become a widespread post-pandemic disease? A debate on the organs most affected |
Francesco Ferrara, Andrea Zovi, Marta Masi, Roberto Langella, Ugo Trama, Mariarosaria Boccellino, Antonio Vitiello |
| 14 |
[GO] |
2023―Jan―12 |
Drug consumption in German cities and municipalities during the COVID-19 lockdown: a wastewater analysis |
Reinhard Oertel, Sara Schubert, Björn Helm, Robin Mayer, Roger Dumke, Ali El-Armouche, Bertold Renner |
| 15 |
[GO] |
2022―Dez―12 |
Hospital and laboratory outcomes of patients with COVID-19 who received vitamin D supplementation: a systematic review and meta-analysis of randomized controlled trials |
Mohamed Sayed Zaazouee, Mahmoud Eleisawy, Amira M. Abdalalaziz, Mahmoud M. Elhady, Omar Adel Ali, Taghreed Mohamed Abdelbari, et al. (+13) Sara Mohamed Hasan, Hossam Waleed Almadhoon, Alaa Yehia Ahmed, Alaa Shaban Fassad, Rewan Elgendy, Eman Adnan Abdel-Baset, Hamis A. Elsayed, Ahmed Bostamy Elsnhory, Alaa Bahaaeldin Abdraboh, Hazem Metwally Faragalla, Alaa Ahmed Elshanbary, Osama A. Kensara, Mohamed M. Abdel-Daim |
| 16 |
[GO] |
2022―Dez―03 |
Cholinergic dysfunction in COVID-19: frantic search and hoping for the best |
Eman Hassan Nadwa, Hayder M. Al-Kuraishy, Ali I. Al-Gareeb, Engy Elekhnawy, Sarah M. Albogami, Mohammed Alorabi, et al. (+2) Gaber El-Saber Batiha, Michel De Waard |
| 17 |
[GO] |
2022―Sep―05 |
Citicoline and COVID-19: vis-à-vis conjectured |
Hayder M. Al-kuraishy, Ali K. Al-Buhadily, Ali I. Al-Gareeb, Mohammed Alorabi, Nasser A. Hadi Al-Harcan, Maisra M. El-Bouseary, Gaber El-Saber Batiha |
| 18 |
[GO] |
2022―Jul―02 |
Pandemic COVID-19, an update of current status and new therapeutic strategies |
Antonio Vitiello, Raffaele La Porta, Ugo Trama, Francesco Ferrara, Andrea Zovi, Amogh Milind Auti, et al. (+2) Marina Di Domenico, Mariarosaria Boccellino |
| 19 |
[GO] |
2022―Jun―03 |
Potential effects of icariin, the Epimedium-derived bioactive compound in the treatment of COVID-19: a hypothesis |
Mohammad Rafi Khezri, Fereshteh Nazari-Khanamiri, Tooba Mohammadi, Donya Moloodsouri, Morteza Ghasemnejad-Berenji |
| 20 |
[GO] |
2022―Mrz―18 |
COVID-19 pandemic-related adaptations of medical education in clinical pharmacology - impact on students and lecturers at a German university |
Susanne Hafner, Oliver Zolk, Holger Barth |
| 21 |
[GO] |
2022―Jan―31 |
Vitamin D can reduce severity in COVID-19 through regulation of PD-L1 |
Hatice Aygun |
| 22 |
[GO] |
2022―Jan―28 |
Bradykinin-target therapies in SARS-CoV-2 infection: current evidence and perspectives |
Manuele Figueiredo da Silva, João Xavier de Araújo-Júnior, Edeildo Ferreira da Silva-Júnior, Luana Heimfarth, Paulo Ricardo Martins-Filho, Jullyana de Souza Siqueira Quintans, Lucindo José Quintans-Júnior |
| 23 |
[GO] |
2021―Nov―05 |
Correction to: The renin-angiotensin system and specifically angiotensin-converting enzyme 2 as a potential therapeutic target in SARS-CoV-2 infections |
Francesco Ferrara, Antonio Vitiello |
| 24 |
[GO] |
2021―Okt―20 |
Association and pharmacological synergism of the triple drug therapy baricitinib/remdesivir/rhACE2 for the management of COVID-19 infection |
Antonio Vitiello, Francesco Ferrara |
| 25 |
[GO] |
2021―Okt―20 |
Would carvacrol be a supporting treatment option effective in minimizing the deleterious effects of COVID-19? |
Fernanda Oliveira de Carvalho, Jessica Paloma Rosa Silva, Érika Ramos Silva, Ricardo Luiz Cavalcanti de Albuquerque Júnior, Paula Santos Nunes, Adriano Antunes de Souza Araújo |
| 26 |
[GO] |
2021―Sep―30 |
miRNA-223 as a regulator of inflammation and NLRP3 inflammasome, the main fragments in the puzzle of immunopathogenesis of different inflammatory diseases and COVID-19 |
Sheyda Houshmandfar, Ali Saeedi-Boroujeni, Mohammad Rashno, Ali Khodadadi, Mohammad-Reza Mahmoudian-Sani |
| 27 |
[GO] |
2021―Sep―04 |
Covid-19 and development of heart failure: mystery and truth |
Hope Onohuean, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Safaa Qusti, Eida M. Alshammari, Gaber El-Saber Batiha |
| 28 |
[GO] |
2021―Jun―21 |
The renin-angiotensin system and specifically angiotensin-converting enzyme 2 as a potential therapeutic target in SARS-CoV-2 infections |
Francesco Ferrara, Antonio Vitiello |
| 29 |
[GO] |
2021―Mai―07 |
Current understanding on molecular drug targets and emerging treatment strategy for novel coronavirus-19 |
Khadga Raj, Karamjeet Kaur, G. D. Gupta, Shamsher Singh |
| 30 |
[GO] |
2021―Feb―18 |
Interferon-beta offers promising avenues to COVID-19 treatment: a systematic review and meta-analysis of clinical trial studies |
Ailar Nakhlband, Ali Fakhari, Hosein Azizi |
| 31 |
[GO] |
2021―Jan―14 |
Efficacy of synthetic glucocorticoids in COVID-19 endothelites |
Francesco Ferrara, Antonio Vitiello |
| 32 |
[GO] |
2021―Jan―08 |
Chloroquine/hydroxychloroquine: an inflammasome inhibitor in severe COVID-19? |
Mohammad Bahadoram, Bijan Keikhaei, Ali Saeedi-Boroujeni, Mohammad-Reza Mahmoudian-Sani |
| 33 |
[GO] |
2021―Jan―04 |
NF-κB signalling as a pharmacological target in COVID-19: potential roles for IKKβ inhibitors |
Mahesh Kandasamy |
| 34 |
[GO] |
2020―Sep―06 |
Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis |
Yanxiang Zang, Xuejie Han, Meijiao He, Jing Shi, Yue Li |
| 35 |
[GO] |
2020―Mai―27 |
Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action |
Emanuele Rizzo |
| 36 |
[GO] |
2020―Mai―25 |
Vitamin D can prevent COVID-19 infection-induced multiple organ damage |
Hatice Aygun |
| 37 |
[GO] |
2020―Mai―19 |
A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19) |
Maryam Rameshrad, Majid Ghafoori, Amir Hooshang Mohammadpour, Mohammad Javad Dehghan Nayeri, Hossein Hosseinzadeh |
| 38 |
[GO] |
2020―Mai―15 |
COVID-19 pandemic and therapy with ibuprofen or renin-angiotensin system blockers: no need for interruptions or changes in ongoing chronic treatments |
Oliver Zolk, Susanne Hafner, Christoph Q. Schmidt |
